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PTP-PEST is a ubiquitously expressed, cytosolic, mammalian protein tyrosine phosphatase (PTP) which
exhibits high specific activity in vitro. We have investigated the substrate specificity of PTP-PEST by a novel
substrate-trapping approach in combination with in vitro dephosphorylation experiments. We initially iden-
tified a prominent 130-kDa tyrosine-phosphorylated protein in pervanadate-treated HeLa cell lysates which
was preferentially dephosphorylated by PTP-PEST in vitro. In order to identify this potential substrate, mutant
(substrate-trapping) forms of PTP-PEST were generated which lack catalytic activity but retain the ability to
bind substrates. These mutant proteins associated in stable complexes exclusively with the same 130-kDa
protein, which was identified as p130cas by immunoblotting. This exclusive association was observed in lysates
from several cell lines and in transfected COS cells, but was not observed with other members of the PTP
family, strongly suggesting that p130cas represents a major physiologically relevant substrate for PTP-PEST.
Our studies suggest potential roles for PTP-PEST in regulation of p130cas function. These functions include
mitogen- and cell adhesion-induced signalling events and probable roles in transformation by various onco-
genes. These results provide the first demonstration of a PTP having an inherently restricted substrate
specificity in vitro and in vivo. The methods used to identify p130cas as a specific substrate for PTP-PEST are
potentially applicable to any PTP and should therefore prove useful in determining the physiological substrates
of other members of the PTP family.
The protein tyrosine phosphatase (PTP) family of enzymes
consists of more than 75 structurally diverse proteins which
have in common the highly conserved 250-amino-acid PTP
catalytic domain, but which display considerable variation in
their noncatalytic segments (5, 56). This structural diversity
presumably reflects the diversity of physiological roles of indi-
vidual PTP family members, which in certain cases have been
demonstrated to have specific functions in growth, develop-
ment, and differentiation (11, 25, 36, 39, 49). Although recent
studies have also generated considerable knowledge regarding
the structure, expression, and regulation of PTPs, the nature of
the tyrosine-phosphorylated substrates through which the
PTPs exert their effects remains to be determined. Studies with
a limited number of synthetic phosphopeptide substrates have
demonstrated some differences in substrate selectivity of dif-
ferent PTPs (7, 8) and have indicated preferences for certain
amino acid residues at particular positions around the phos-
phorylated tyrosine residue (44, 63). This indicates that PTPs
display a certain level of substrate selectivity in vitro, although
the physiological relevance of the substrates used in these
studies is unclear.
PTP-PEST is an 88-kDa cytosolic PTP (6, 9, 54, 58, 59)
which is expressed ubiquitously in mammalian tissues (60) and
which exhibits high specific activity when assayed in vitro with
artificial tyrosine-phosphorylated substrates (15). We have pre-
viously demonstrated that PTP-PEST is subject to regulation
via phosphorylation of Ser-39 in vitro and in vivo. This modi-
fication is catalyzed by both protein kinase C and protein
kinase A and results in reduced enzyme activity as a conse-
quence of an increase in the Km of the dephosphorylation
reaction (15). It appears likely that further regulatory mecha-
nisms exist for PTP-PEST, since this enzyme would be ex-
pected to exert a considerable negative influence on the ty-
rosine phosphorylation state of cytosolic substrates of tyrosine
kinases. One possibility is that this influence could be limited
by the substrate specificity of PTP-PEST, of which details are
currently lacking.
The crystal structures of PTP1B alone (2) and in a complex
with a phosphotyrosine-containing peptide (21) were recently
determined. These structures indicated roles for the invariant
residues of the PTP catalytic domain and suggested a mecha-
nism for catalysis which is consistent with the available kinetic
data and which may be applicable to PTPs in general (3). After
binding of phosphotyrosine in the active site cleft, a thiol-
phosphate intermediate is formed between the substrate and
the active site cysteine residue (17). In addition, substrate
binding induces movement of a loop that forms one side of the
active site cleft (equivalent to amino acids 179 to 187 in PTP1B
and residues 197 to 205 in PTP-PEST), resulting in a more
closed structure around the active site. In PTP1B, this confor-
mation is stabilized by hydrophobic interactions between the
phosphotyrosine phenyl ring and the side chain of Phe-182.
The movement of this loop brings the side chain of an invari-
ant, catalytically essential aspartic acid residue (Asp-181,
equivalent to Asp-199 in PTP-PEST) into position to act as a
general acid in the catalytic mechanism (10, 64); by donating a
proton to the substrate tyrosine residue, this aspartic acid res-
idue destabilizes the transition-state intermediate, resulting in
the release of the dephosphorylated peptide from the active
site. The essential catalytic role of Asp-181 in PTP1B is sup-
ported by the kinetic properties of a mutant protein in which
this residue is changed to Ala (13). The resultant enzyme
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displays a similar Km but a greatly reduced Vmax compared with
the wild-type enzyme. These observations suggested that the
D181A (D-1813A change) mutant enzyme could potentially
yield an inactive enzyme which largely retains the ability to
bind substrates; these properties would clearly be useful for
trapping potential PTP substrates to facilitate their isolation
and identification. We have utilized such a mutant form of
PTP-PEST in these experiments.
We have used pervanadate-treated cells as an abundant
source of tyrosine-phosphorylated proteins to investigate the sub-
strate specificity of PTP-PEST. Using a combination of in vitro
dephosphorylation and substrate-trapping experiments, we
have found that PTP-PEST exclusively selects p130cas as a
substrate from complex mixtures of 50 to 100 phosphotyrosine-
containing proteins. Our results strongly suggest that the phys-
iological role of PTP-PEST involves regulation of the phosphor-
ylation state of p130cas and are the first direct demonstration of
a PTP having an inherently restricted substrate specificity.
MATERIALS AND METHODS
Generation, expression, and purification of mutant PTP proteins. Point mu-
tations within the catalytic domains of PTP-PEST (D199A and C231S) and
PTP1B (D181A and C215S) were introduced by site-directed mutagenesis with
the Muta-Gene in vitro mutagenesis kit (Bio-Rad, Richmond, Calif.). Regions
containing the required point mutation were then exchanged with the wild-type
sequences within appropriate expression vectors, and the replaced mutant re-
gions were sequenced in their entirety to verify the absence of additional muta-
tions.
Full-length PTP-PEST proteins (wild-type and mutant proteins, containing
either Asp-1993Ala or Cys-2313Ser mutations) and the wild-type PTP-PEST
catalytic domain (amino acids 1 to 305) were expressed in Sf9 cells with recom-
binant baculovirus (BaculoGold; Pharmingen, San Diego, Calif.) and purified as
described in reference 15. Truncated forms of wild-type and mutant PTP-PEST
proteins, comprising amino acid residues 1 to 305 of PTP-PEST, were also
expressed in Escherichia coli as glutathione S-transferase (GST) fusion proteins
after subcloning of PTP-PEST DNA in frame downstream of GST in pGEX
vectors (Pharmacia Biotech, Inc., Uppsala, Sweden). E. coli cells (25 ml) trans-
formed with the appropriate vector were grown to log phase (optical density at
600 nm of approximately 0.5). Fusion protein expression was then induced by
addition of 0.2 mM isopropyl-1-thio-b-D-galactopyranoside, and the cells were
grown for 2 to 4 h at 308C. Cells were harvested by centrifugation, incubated with
50 mg of lysozyme per ml in 3 ml of buffer containing 50 mM Tris-HCl (pH 7.4),
5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 5 mg of
leupeptin per ml, 5 mg of aprotinin per ml, 0.1% Triton X-100, and 150 mM
NaCl, and then lysed by sonication (three times for 10 s each). After removal of
insoluble material by centrifugation (20 min at 300,0003 g), fusion proteins were
isolated by incubation for 30 min at 48C with 100 ml of glutathione-Sepharose
beads (Pharmacia Biotech, Inc.). The beads were then collected by centrifuga-
tion and washed three times with buffer A (20 mM Tris-HCl, [pH 7.4], 1 mM
EDTA, 1 mM benzamidine, 1 mg of leupeptin per ml, 1 mg of aprotinin per ml,
10% glycerol, 1% Triton X-100, 100 mM NaCl). This procedure yielded essen-
tially homogeneous fusion protein at a concentration of 1 mg of protein per ml
of glutathione-Sepharose beads. PTP1B proteins (wild-type and mutant forms)
comprising amino acids 1 to 321 were expressed in E. coli cells and purified to
homogeneity as described in reference 4.
Cell culture, transfection, preparation of lysates, and fractionation. HeLa
(ATCC CCL 2) and COS1 (ATCC CRL 1650) cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 5% fetal bovine serum; Wi38
(ATCC CCL 75), C2C12 (ATCC CRL 1772), and MvLu (ATCC CCL 64) cells
were grown in DMEM containing 10% fetal bovine serum; 293 (ATCC CRL
1573) cells were grown in DMEM containing 10% calf serum; and MCF10A
(ATCC CRL 10317) cells were grown in 50% DMEM–50% Ham’s F-12 medium
containing 5% horse serum, 20 ng of epidermal growth factor per ml, 10 mg of
insulin per ml, 0.5 mg of hydrocortisone per ml, and 0.25 mg of amphotericin B
(Fungizone) per ml. All media also contained penicillin and streptomycin at 100
U/ml and 100 mg/ml, respectively, and all cells were grown at 378C.
Calcium phosphate-mediated transfection was used to introduce cDNA en-
coding wild-type and mutant PTP-PEST proteins into COS cells. These were
encoded by PTP-PEST cDNA subcloned into the plasmid PMT2, from which
expression is driven by an adenovirus major late promoter; 20 mg of DNA was
used for transfection of each 10-cm-diameter plate of cells. The level of expres-
sion of PTP-PEST constructs was similar in all cases.
Prior to cell lysis, 70 to 90% confluent cultures of cells were treated for 30 min
with 0.1 mM pervanadate (20 ml of a fresh solution containing 50 mM sodium
metavanadate [NaVO3] and 50 mM H2O2 was added to 10 ml of medium).
Treatment of cells with H2O2 and vanadate leads to a synergistic increase in
phosphotyrosine levels, presumably due to inhibition of intracellular PTPs by
vanadate. The synergism between H2O2 and vanadate has previously been sug-
gested to result from improved accumulation of the resultant oxidized vanadate
(pervanadate) within the cells compared with vanadate itself (19). Pervanadate
treatment resulted in the appearance of at least 50 prominent phosphotyrosine
protein bands in all cell types, whereas untreated cells contained virtually unde-
tectable levels of phosphotyrosine (data not shown).
Cells were lysed in buffer A containing 5 mM iodoacetic acid, which was in-
cluded in order to inhibit irreversibly cellular PTPs. After incubation at 48C for
30 min, 10 mM dithiothreitol was added to inactivate any unreacted iodoacetic
acid; insoluble material was then removed by centrifugation for 20 min at
300,000 3 g. The resultant lysates were stable with regard to their phosphoty-
rosine content during long-term (several months) storage at 2708C and during
prolonged (at least 20 h) incubation at 48C in the absence of exogenously added
PTPs.
Pervanadate-treated HeLa cell lysate was fractionated by anion-exchange
chromatography with a Mono Q fast-performance liquid chromatography
(FPLC) column (Pharmacia). The sample (50 mg of total protein at 3 mg/ml in
buffer A) was diluted in 3 volumes of buffer B (20 mM Tris-HCl [pH 7.4], 1 mM
EDTA, 1 mM benzamidine, 1 mg of leupeptin per ml, 1 mg of aprotinin per ml,
0.1% Triton X-100) prior to loading. Proteins were eluted at a flow rate of 1
ml/min with a linear gradient of 0 to 0.5 M NaCl in buffer B over 20 fractions
(1-ml fraction volume), followed by a second gradient of 0.5 to 1.0 M NaCl in
buffer B over 5 fractions. Phosphotyrosine-containing proteins were detected
within fractions 7 to 21 according to antiphosphotyrosine immunoblotting.
Dephosphorylation reactions. Lysates of pervanadate-treated HeLa cells (1 to
2 mg of protein per ml) containing tyrosine-phosphorylated proteins were incu-
bated on ice in the absence or presence of purified active PTPs. Dephosphory-
lation was terminated by the removal of aliquots (30 mg of protein) into sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer,
and the extent of dephosphorylation was determined by immunoblotting with the
monoclonal antibody G104. Assays of PTP activity with tyrosine-phosphorylated
32P-labelled RCM-lysozyme as the substrate were performed as described in
reference 12.
Antibodies and immunoblotting. The PTP-PEST monoclonal antibody AG25
was raised against baculovirus-expressed purified full-length PTP-PEST. The
antiphosphotyrosine monoclonal antibody G104 was generated with, as the an-
tigen, phosphotyrosine, alanine, and glycine in a 1:1:1 ratio polymerized in the
presence of keyhole limpet hemocyanin with 1-ethyl-3-(39-dimethylaminopropyl)
carbodiimide, a method originally described in reference 22. p130cas monoclonal
antibody was from Transduction Laboratories (Lexington, Ky.); p130cas poly-
clonal antibody was provided by Amy Bouton (University of Virginia). Mono-
clonal antibody FG6 against PTP1B was provided by David Hill (Calbiochem
Oncogene Research Products, Cambridge, Mass.). Visualization of proteins by
immunoblotting was achieved by enhanced chemiluminescence with horseradish
peroxidase (HRP)-conjugated secondary antibodies (Amersham Life Science,
Inc., Arlington Heights, Ill.) and the SuperSignal CL-HRP substrate system
(Pierce, Rockford, Ill.).
Immunoprecipitation and substrate trapping. Immunoprecipitation of PTP-
PEST from transfected COS cells was performed after covalent coupling of
monoclonal antibody AG25 to protein A-Sepharose beads (Pharmacia Biotech,
Inc.) with the chemical cross-linking agent dimethyl pimelimidate (48). Antibody
was first bound to protein A-Sepharose at a concentration of 1 mg/ml of bead
volume, and unbound material was then removed by three washes with 0.2 M
sodium borate (pH 9). Covalent coupling was achieved by incubation at room
temperature for 30 min in the presence of 20 mM dimethyl pimelimidate in 0.2
M sodium borate (pH 9). The beads were then incubated for 1 h with an excess
of 0.2 M ethanolamine (pH 8) to block any unreacted cross-linker and washed
three times with phosphate-buffered saline prior to storage at 48C. AG25 beads
(10 ml) were used to precipitate transfected PTP-PEST from lysates containing
approximately 0.375 mg of protein.
Substrate trapping was performed with various PTP affinity matrices. The
full-length PTP-PEST matrix utilized covalent coupled AG25-protein A-Sepha-
rose beads to which purified baculovirus-expressed PTP-PEST protein was
bound. Aliquots (10 ml) of AG25 beads were incubated for 2 h at 48C in 100 ml
of buffer A in the presence of 5 mg of purified PTP-PEST (wild-type or mutant
forms); unbound PTP-PEST was then removed by three washes with 1 ml of
buffer A. The resultant PTP-PEST–AG25–protein A–Sepharose beads con-
tained approximately 2 mg of PTP-PEST per 10-ml aliquot. Substrate trapping
was also carried out with glutathione-Sepharose beads bound to bacterially
expressed GST fusion proteins containing the catalytic domain of PTP-PEST.
PTP1B was also used in substrate-trapping experiments. In this case, the mono-
clonal antibody FG6 was precoupled to protein A-Sepharose in the absence of
cross-linker (2 mg of antibody per 10 ml of beads), and then purified PTP1B
proteins were added in excess and incubated at 48C for 2 h. After removal of
unbound PTP1B, 10 ml of beads contained approximately 2 mg of PTP1B.
Pervanadate-treated cell lysates, or column fractions, were used as a source of
phosphotyrosine-containing proteins for substrate-trapping experiments. In gen-
eral, lysates containing 0.25 to 0.5 mg of protein in 0.5 ml of buffer A (including
5 mM iodoacetic acid and 10 mM dithiothreitol) were incubated at 48C for 2 h
in the presence of 10 ml of affinity matrix containing approximately 2 mg of the
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FIG. 1. PTP-PEST selectively dephosphorylates a 130-kDa phosphotyrosine-containing protein from pervanadate-treated HeLa cell lysates. Aliquots of pervana-
date-treated HeLa cell lysates were incubated on ice in the absence [60 (2) lanes] or in the presence of 2 nM purified full-length PTP-PEST (A, upper panel) or the
indicated concentrations of PTP-PEST catalytic domain (B, left panel) or PTP1B (37-kDa form) (B, right panel). At the indicated time points (minutes) aliquots
containing 30 mg of protein were removed into SDS-PAGE sample buffer; phosphotyrosine content was then analyzed by immunoblotting. In panel A, the region below
the dashed line was exposed longer (5 min compared with 15 s for the upper portion) in order to display the weak phosphotyrosine bands present in this part of the
blot. The lower panel in A is a reprobe of the 130-kDa region of the immunoblot with a rabbit polyclonal antibody to p130cas. Sizes are shown in kilodaltons.
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appropriate PTP protein. Unbound proteins were then removed from the sam-
ples by three washes with 1 ml of buffer A, and bound material was collected by
addition of 50 ml of SDS-PAGE sample buffer followed by heating at 958C for 5
min; proteins bound to the beads were then analyzed by SDS-PAGE followed by
immunoblotting.
RESULTS
PTP-PEST preferentially dephosphorylates a 130-kDa phos-
photyrosine-containing protein present in pervanadate-treat-
ed HeLa cell lysates. In order to investigate the substrate
specificity of PTP-PEST in vitro, HeLa cells were treated with
pervanadate, yielding 50 to 100 distinct phosphotyrosine-con-
taining proteins, as judged by immunoblotting of the cell lysate
with the monoclonal antiphosphotyrosine antibody G104 (Fig.
1). Purified full-length PTP-PEST (expressed in Sf9 cells with
recombinant baculovirus) was then added to the lysate, and
aliquots were removed at various time points for analysis by
SDS-PAGE followed by antiphosphotyrosine immunoblotting.
Surprisingly, a prominent 130-kDa phosphotyrosine protein
(p130) was selectively dephosphorylated by PTP-PEST within
10 min, whereas the intensity of the other bands was essentially
unchanged even after 60 min of incubation with PTP-PEST
(Fig. 1A). Long incubations with higher concentrations of
PTP-PEST (greater than 100-fold) resulted in the complete
FIG. 2. Identification of the 130-kDa phosphotyrosine-containing protein as
p130cas. Pervanadate-treated HeLa cell lysate containing 50 mg of total protein
was fractionated on a Mono Q FPLC column, and aliquots of the indicated
fractions were analyzed by SDS-PAGE followed by immunoblotting with anti-
phosphotyrosine (upper panel) or anti-p130cas (lower panel) antibodies (A). All
other column fractions (1 to 6 and 21 to 30) contained essentially no phospho-
tyrosine bands. Lanes marked L and R refer to initial lysate and column run-
through samples, respectively. (B) Aliquots (0.5 ml) of all samples analyzed in
panel A were incubated with an affinity matrix containing a substrate-trapping
PTP-PEST mutant, comprising full-length PTP-PEST (D199A) bound to co-
valently coupled protein A-Sepharose-antibody (AG25) beads. Proteins associ-
ated with PTP-PEST were then analyzed by SDS-PAGE followed by immuno-
blotting with antiphosphotyrosine (upper panel) or anti-p130cas (lower panel)
antibodies. (C) Pervanadate-treated HeLa cell lysate was immunodepleted of
p130cas by three successive immunoprecipitations (ip) with a polyclonal rabbit
antibody to p130cas. D199A PTP-PEST affinity matrix was then used as in panel
B to isolate phosphotyrosine-containing proteins from the lysate and from the
depleted supernatants (s/n) of each of the sequential p130cas immunoprecipita-
tions (s/n 1, s/n 2, and s/n 3). Left panels correspond to the starting material used
in the substrate-trapping incubations; the right panels correspond to the proteins
associated with D199A PTP-PEST. Upper panels were immunoblotted with
monoclonal antiphosphotyrosine antibody G104, and lower panels were immu-
noblotted with polyclonal anti-p130cas antibody. Sizes are shown in kilodaltons.
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removal of all phosphotyrosine bands from the lysate. How-
ever, under all conditions tested, p130 was found to be dephos-
phorylated more rapidly than all other proteins present.
The selective dephosphorylation of p130 by PTP-PEST was
also observed with a truncated form of the phosphatase (amino
acid residues 1 to 305) which essentially contains only the
catalytic domain of the enzyme (Fig. 1B, left panel). This result
suggests that the striking substrate preference displayed by
PTP-PEST in this analysis is an inherent property of the phos-
phatase catalytic domain, whereas the C-terminal 500 amino
acid residues have little discernible effect on the substrate
specificity of the enzyme.
The specificity of the interaction between PTP-PEST and
p130 was addressed with the catalytic domain of PTP1B (ami-
no acid residues 1 to 321) in dephosphorylation reactions.
When added at molar concentrations similar to those used for
the catalytic domain of PTP-PEST, PTP1B was found to de-
phosphorylate fully most of the phosphotyrosine-containing
proteins present in the pervanadate-treated HeLa lysate (Fig.
1B). In addition, the time course of dephosphorylation of p130
was not significantly more rapid than that of the other phos-
photyrosine proteins dephosphorylated by PTP1B. PTP-PEST
and PTP1B display similar specific activities (40,000 to 50,000
U/mg of protein) when assayed in vitro (4, 15); the ability of
PTP1B to dephosphorylate all tyrosine-phosphorylated pro-
teins present under conditions in which PTP-PEST exclusively
dephosphorylates p130cas (Fig. 1B, 30-min incubations at 5 to
10 nM PTP) therefore suggests that the substrate specificity of
PTP-PEST is relatively stringent and that p130 is a potential
physiologically significant substrate for PTP-PEST.
Identification of the phosphotyrosine-containing p130 pro-
tein as p130cas by substrate trapping with an inactive mutant
form of PTP-PEST. Phosphotyrosine-containing proteins from
a pervanadate-treated HeLa cell lysate were fractionated by
anion-exchange chromatography with a Mono Q FPLC col-
umn. Antiphosphotyrosine immunoblotting of the resultant
column fractions showed that the p130 phosphotyrosine pro-
tein eluted as a single peak in fractions 11 to 14 (approximately
0.3 M NaCl) (Fig. 2A, upper panel). In view of the abundance
of tyrosine-phosphorylated p130 in HeLa lysates, it appeared
likely that p130 represents a previously identified phosphoty-
rosine-containing 130-kDa protein. Several potential candi-
dates were identified in the literature, including the focal ad-
hesion kinase p125FAK, Ras-GAP, gp130, and p130cas. Of these
candidates, p130cas has been identified as a particularly prom-
inent phosphotyrosyl protein in a wide variety of systems, in-
cluding v-crk (30, 32) and src (23, 42)-transformed fibroblasts,
integrin-mediated cell adhesion (35, 37, 57), and cells stimu-
lated by a variety of mitogenic agents (27, 41, 43, 50, 61).
Therefore we tested the possibility that the p130 phosphoty-
rosine protein corresponds to p130cas by immunoblotting the
Mono Q fractions with an antibody to p130cas. The 130-kDa
band corresponding to p130cas eluted in the same fractions as
the p130 tyrosine-phosphorylated protein and displayed a sim-
ilar apparent molecular mass (Fig. 2A, lower panel), suggesting
that they might represent the same protein. Furthermore,
p130cas immunoprecipitated from these fractions was found to
be phosphorylated on tyrosyl residues (data not shown).
A mutant form of PTP-PEST (D199A) was generated by
site-directed mutagenesis; the mutant enzyme was then puri-
fied after expression with recombinant baculovirus. When as-
sayed with tyrosine-phosphorylated RCM-lysozyme as a sub-
strate, the purified mutant enzyme exhibited a specific activity
which was approximately 10,000-fold lower than that of the
wild-type enzyme (16). This purified protein was bound to an
affinity matrix composed of an anti-PTP-PEST monoclonal
antibody (AG25) covalently coupled to protein A-Sepharose
beads and was then incubated with each of the Mono Q frac-
tions. After 45 min of incubation, proteins associating with the
mutant PTP-PEST were collected by centrifugation, the beads
were washed, and SDS-PAGE sample buffer was added. As-
sociated proteins were then analyzed by immunoblotting with
the monoclonal antiphosphotyrosine antibody G104. The mu-
tant PTP-PEST protein was found to associate with a single
phosphotyrosine-containing protein, the molecular mass (130
kDa) and Mono Q elution position (fractions 11 to 14) of
which coincided with those of p130cas (Fig. 2B, upper panel).
Immunoblotting of the PTP-PEST-associated proteins with the
p130cas antibody demonstrated that the 130-kDa tyrosine-
phosphorylated protein trapped by the mutant PTP-PEST is
indeed p130cas (Fig. 2B, lower panel). These data further sup-
port the notion that p130cas is a potential physiologically rele-
vant substrate for PTP-PEST.
In order to confirm that p130cas alone is recognized by PTP-
PEST, p130cas protein was specifically depleted from the ly-
sates by immunoprecipitation. When these samples were sub-
sequently incubated with mutant PTP-PEST, none of the
remaining tyrosine-phosphorylated proteins associated with
the mutant enzyme (Fig. 2C), indicating that the 130-kDa
tyrosine-phosphorylated protein observed in mutant PTP-
PEST precipitates consists solely of p130cas.
Having identified the tyrosine-phosphorylated protein asso-
ciated with the mutant form of PTP-PEST as p130cas, the
antiphosphotyrosine immunoblot from Fig. 1A was reprobed
FIG. 3. Specificity of the interaction between inactive mutant PTP-PEST and
tyrosine-phosphorylated p130cas. Various affinity matrices were incubated with
0.3 mg of pervanadate-treated HeLa cell lysate, and proteins associated with the
beads were analyzed by SDS-PAGE followed by immunoblotting with anti-
phosphotyrosine (upper panel) or anti-p130cas (lower panel) antibodies. FL PTP-
PEST matrix consists of full-length PTP-PEST proteins bound to covalently
coupled protein A-Sepharose-antibody (AG25) beads; CD PTP-PEST matrix
consists of glutathione-Sepharose beads with GST fusion proteins containing
amino acids 1 to 305 of PTP-PEST; PTP1B (37k) matrix consists of amino acids
1 to 321 of PTP1B coupled to protein A-Sepharose-antibody (FG6) beads.
Control samples (2) consisted of matrix alone (antibody-protein A-Sepharose or
glutathione-Sepharose beads); GST sample contained glutathione transferase
protein; WT refers to wild-type PTP proteins; other samples contained the
indicated point mutations. The lane marked L consists of 30 mg of lysate protein.
The prominent band at 50 kDa in the PTP1B lanes corresponds to the antibody
heavy chain. Sizes are shown in kilodaltons.
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with a p130cas polyclonal antibody (Fig. 1A, lower panel). The
band corresponding to p130cas migrated at the same molecular
mass as the 130-kDa phosphotyrosine-containing protein
which was rapidly dephosphorylated by PTP-PEST. Further-
more, p130cas displayed increased electrophoretic mobility
within 10 min of incubation with PTP-PEST, indicating that
p130cas was rapidly dephosphorylated by PTP-PEST under
these conditions. In addition, these data confirm that the ob-
served reduction in antiphosphotyrosine antibody staining
(Fig. 1A, upper panel) was due to the dephosphorylation of
p130cas by PTP-PEST and was not due to proteolysis during
the incubation.
Determination of structural features of PTP-PEST involved
in the specific interaction with tyrosine-phosphorylated p130cas.
The interaction between p130cas and PTP-PEST was investi-
gated further in substrate-trapping experiments using various
purified mutant forms of PTP-PEST to precipitate proteins
from pervanadate-treated HeLa lysates. The wild-type full-
length phosphatase was found to be incapable of stable asso-
ciation with tyrosine-phosphorylated p130cas, whereas both the
PTP-PEST (D199A) mutant protein and a mutant lacking the
active site cysteine residue (C231S) specifically precipitated
p130cas from the lysate (Fig. 3). The inability of the wild-type
phosphatase to precipitate tyrosine-phosphorylated p130cas
presumably reflects the transient nature of the normal inter-
action between PTP-PEST and tyrosine-phosphorylated p130cas,
which is likely to be concluded as soon as p130cas is dephos-
phorylated by PTP-PEST.
Since the C-terminal 500-amino-acid segment of PTP-PEST
contains several proline-rich regions which resemble Src ho-
mology 3 (SH3) domain binding sequences, it appeared plau-
sible that the specificity of the interaction between PTP-PEST
and p130cas might depend to some extent on association of
these segments with the SH3 domain of p130cas. The possible
contribution of the C-terminal segment of PTP-PEST in the
observed specific interaction of PTP-PEST with p130cas was
therefore addressed in further substrate-trapping experiments
with GST fusion proteins containing the catalytic domain of
PTP-PEST alone in both wild-type and mutant (D199A)
forms. The mutant catalytic domain of PTP-PEST fused to
GST was found to precipitate phosphotyrosyl p130cas specifi-
cally, whereas both the wild-type fusion protein and GST alone
failed to precipitate tyrosine-phosphorylated p130cas (Fig. 3).
The specific interaction between PTP-PEST and p130cas ob-
served in these experiments therefore appears to be an intrin-
sic property of the catalytic domain of PTP-PEST, emulating
the observed preference of the active PTP-PEST catalytic do-
main for dephosphorylation of p130cas in vitro (Fig. 1B).
Specificity of the interaction between mutant PTP-PEST
and tyrosine-phosphorylated p130cas. In view of the relative
abundance of tyrosine-phosphorylated p130cas in the pervana-
date-treated HeLa cell lysate (Fig. 1), we considered the
possibility that the observed selective binding of PTP-PEST
substrate-trapping mutant proteins to p130cas was substrate
directed (reflecting the abundance of this potential substrate
relative to the other phosphotyrosine-containing proteins
present in the lysate) rather than enzyme directed (reflecting a
genuine substrate preference of PTP-PEST); this possibility
was addressed in two ways. First, inactive mutant forms of the
catalytic domain of PTP1B were used to trap potential sub-
strates for this enzyme from the pervanadate-treated HeLa
lysates. Again, we found that the wild-type phosphatase was
incapable of stable interaction with any phosphotyrosine-con-
taining protein, whereas mutant variants of the PTP1B phos-
phatase domain (comprising Cys or Asp mutations analogous
to those described above for PTP-PEST) associated with many
tyrosine-phosphorylated proteins (Fig. 3). This was especially
apparent for the aspartic acid mutant of PTP1B (D181A),
which appeared to precipitate essentially all phosphotyrosine-
containing proteins from the lysate with similar efficacy (com-
pare Fig. 3, lysate and PTP1B D181A lanes). The C215S mu-
tant of PTP1B displayed lower affinity for phosphotyrosine-
containing proteins than the D181A mutant; however, longer
exposure of the immunoblot in Fig. 3 demonstrated that the
FIG. 4. Interaction of inactive mutant PTP-PEST with tyrosine-phosphorylated p130cas from different cell lines. The indicated cell lines were treated with
pervanadate, and the resultant lysates (30 mg of total protein) were analyzed by SDS-PAGE followed by antiphosphotyrosine immunoblotting (A). Aliquots (0.3 mg)
were incubated with the PTP-PEST (D199A) affinity matrix (1) or control matrix (2); the associated proteins were then analyzed by SDS-PAGE and immunoblotting
with antiphosphotyrosine (B) or anti-p130cas (C) antibodies. In panel B, the left portion of the blot (HeLa, Wi38, and 293 samples) was exposed for 5 min, whereas
the remainder was exposed for 30 s.
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C215S mutant of PTP1B was still capable of forming stable
complexes with the majority of the tyrosine-phosphorylated
proteins present (data not shown). These data emphasize the
specific nature of the interaction between PTP-PEST and
p130cas, which appears to be a property peculiar to the PTP-
PEST catalytic domain rather than a feature shared by all PTP
catalytic domains. Nevertheless, it is important to note that in
vivo, the subcellular distribution of the full-length form of
PTP1B is restricted by targeting to the cytoplasmic face of
membranes of the endoplasmic reticulum (14). This subcellu-
lar targeting imposes constraints on substrate recognition by
PTP1B so that only selected substrates are recognized in vivo
(13).
The specificity of the interaction between PTP-PEST and
p130cas was addressed further after pervanadate treatment of
several different cell lines (Wi38, 293, COS, MCF10A, C2C12,
and MvLu), yielding a different array of tyrosine-phosphory-
lated proteins in each case (Fig. 4A). The lysates were then
incubated in the presence of mutant PTP-PEST (D199A), and
tyrosine-phosphorylated proteins associating with PTP-PEST
were analyzed as described in the legend to Fig. 3. In each case,
the D199A mutant PTP-PEST protein precipitated a single
broad phosphotyrosine band with an apparent molecular weight
of between 120,000 and 150,000 in different cell lines, whereas
the affinity matrix alone failed to precipitate any phosphoty-
rosine-containing protein (Fig. 4B). Immunoblotting of the
precipitates with a p130cas antibody revealed that the protein
precipitated from all cell lysates corresponded to p130cas
(Fig. 4C); the observed molecular weight variation between
different cell lines presumably reflects either species differ-
ences in the molecular weight of p130cas, expression of differ-
ent alternatively spliced forms (45), or different levels of ty-
rosine phosphorylation of p130cas. The relative abundance of
tyrosine-phosphorylated p130cas in the PTP-PEST precipitates
appeared to correlate approximately with the abundance of
p130cas protein in the lysates (data not shown). Surprisingly,
regardless of the abundance of tyrosine-phosphorylated p130cas in
the lysates, p130cas was invariably the only phosphotyrosine-
containing protein in the precipitates—even in 293 cell lysates,
which contain very little p130cas protein but which display a
wide variety of other abundantly tyrosine-phosphorylated pro-
teins (Fig. 4A, lane 3). Similarly, when lysates of pervanadate-
treated 293 cells (containing tyrosine-phosphorylated p130cas
in amounts which are undetectable by antiphosphotyrosine
immunoblotting of the lysate) were incubated with active PTP-
PEST (as described in the legend to Fig. 1), no visible dephos-
phorylation of any phosphotyrosine band occurred (16). These
results indicate that the affinity of PTP-PEST for p130cas is
substantially greater than for any other substrate present and
FIG. 5. Vanadate inhibition of the interaction between mutant PTP-PEST
and tyrosine-phosphorylated p130cas. PTP-PEST affinity matrix, comprising full-
length PTP-PEST (D199A or C231S) bound to covalently coupled protein A-
Sepharose-antibody (AG25) beads, was incubated for 10 min on ice in the
presence of the indicated concentrations of sodium orthovanadate (VO4). The
samples were then incubated with aliquots (0.3 mg) of pervanadate-treated HeLa
cell lysate; associated proteins were then analyzed by SDS-PAGE and immuno-
blotting with antiphosphotyrosine (upper panel), anti-p130cas (middle panel), or
anti-PTP-PEST (lower panel) antibodies. The activity of wild-type PTP-PEST
was also determined under the same conditions, with tyrosine-phosphorylated
32P-labelled RCM-lysozyme as a substrate.
FIG. 6. Effect of EDTA on the inhibition of PTP-PEST by vanadate. Full-
length wild-type PTP-PEST was incubated for 5 min with the indicated concen-
trations of sodium orthovanadate in the absence (E) or presence (F) of 5 mM
EDTA. PTP activity against tyrosine-phosphorylated 32P-labelled RCM-ly-
sozyme was then assayed in the presence of the same combinations of inhibitor
and EDTA. All results are expressed relative to the activity of PTP-PEST in the
absence of vanadate and in the presence of 5 mM EDTA.
FIG. 7. Association of endogenous p130cas with transfected PTP-PEST in
COS cells. cDNAs encoding wild-type (WT) or mutant full-length PTP-PEST or
the vector alone (2) were transfected into COS cells, which were treated with
pervanadate for 30 min prior to lysis. Aliquots (30 mg of protein) of each lysate
were immunoblotted with antiphosphotyrosine antibody (left panel). Lysates
(350 mg of protein) were also incubated with covalently coupled protein A–
Sepharose–anti-PTP-PEST (AG25) beads, and associated proteins were ana-
lyzed by SDS-PAGE and immunoblotting with antiphosphotyrosine antibody
(right panel).
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further emphasize the remarkable substrate selectivity of PTP-
PEST for p130cas observed in these experiments.
Association of tyrosine-phosphorylated p130cas with inactive
mutant PTP-PEST is blocked by vanadate. We have consis-
tently observed that, in contrast to the inactive mutant PTP-
PEST, the wild-type enzyme fails to associate in a stable com-
plex with tyrosine-phosphorylated p130cas (Fig. 3), suggesting
that the observed association is active site directed. In order
to investigate this possibility, mutant PTP-PEST (D199A or
C231S) was incubated with the PTP inhibitor vanadate at var-
ious concentrations prior to addition of pervanadate-treated
HeLa cell lysate. The extent of association of p130cas with PTP-
PEST was then analyzed as described in the legend to Fig. 3.
The association of p130cas with D199A PTP-PEST was found
to be potently disrupted by vanadate, with a concentration
dependence similar to that of vanadate inhibition of wild-type
PTP-PEST (Fig. 5, left panels). Surprisingly, C231S PTP-PEST
was unaffected in its ability to associate with p130cas at vana-
date concentrations (0.1 to 1 mM) which significantly disrupted
the association with D199A PTP-PEST, although 10 mM van-
adate effectively blocked the interaction with C231S PTP-
PEST (Fig. 5, right panels). These data support a model for
PTP inhibition by vanadate in which potent enzyme inhibition
arises through direct interaction of vanadate ions with the
thiolate anion of the PTP active site cysteine residue; in the
absence of the cysteine residue, vanadate is therefore a much
less potent inhibitor of enzyme-substrate binding. This model
is supported by recently reported structural data, which indi-
cated the presence of a covalent bond between vanadate and
the active site cysteine residue of the PTP Yop51 (10). Our
data therefore support the notion that the stable association of
mutant PTP-PEST with tyrosine-phosphorylated p130cas is me-
diated by direct interactions between active site residues within
PTP-PEST, in particular the active site cysteine residue, and
phosphotyrosine moieties within p130cas.
The requirement for millimolar concentrations of vanadate
to inhibit both wild-type PTP-PEST activity and the interaction
of p130cas with D199A PTP-PEST was somewhat surprising,
since previous reports have indicated that PTP inhibition oc-
curs at considerably lower vanadate concentrations (58, 62).
This result appears to be a consequence of the presence of
EDTA in both lysis and assay buffers, which we have found to
affect considerably the 50% inhibitory concentration of PTP-
PEST inhibition by vanadate (Fig. 6). Thus, in the absence of
EDTA, the 50% inhibitory concentration of vanadate is ap-
proximately 10 nM, whereas inclusion of 5 mM EDTA in the
assay buffer increases the 50% inhibitory concentration to ap-
proximately 0.3 mM (Fig. 6). This effect appears to result from
chelation of vanadate by EDTA, since intermediate EDTA
concentrations have less effect on the dose-response curve of
PTP-PEST inhibition by vanadate (data not shown). This effect
of EDTA probably accounts for the ability of mutant PTP-
PEST to interact potently with p130cas in lysates of pervana-
date-treated cells prepared in 1 mM EDTA (Fig. 3).
Association of endogenous p130cas with transfected mutant
PTP-PEST in COS cells. The experiments described above
strongly suggest that p130cas represents a potential physiolog-
ically significant substrate for PTP-PEST. In order to assess
whether PTP-PEST interacts with p130cas in intact cells, COS
cells were transfected with plasmids encoding wild-type or mu-
tant forms of PTP-PEST (D199A or C215S). The cells were
treated with pervanadate 30 min prior to lysis, PTP-PEST
proteins were immunoprecipitated, and associated tyrosine-
phosphorylated proteins were analyzed by antiphosphotyrosine
immunoblotting of the resultant precipitates. Under these con-
ditions, the phosphotyrosine-containing band corresponding to
p130cas was again unique in its ability to associate with the
C231S PTP-PEST protein (Fig. 7), indicating that p130cas can
be specifically selected by PTP-PEST as a substrate in an in-
tracellular context in the presence of a large number of alter-
native possible substrates. Neither the wild-type nor the
D199A form of PTP-PEST was capable of a stable interaction
with tyrosine-phosphorylated p130cas in pervanadate-treated
COS cells (Fig. 7). The binding of both wild-type and D199A
PTP-PEST to tyrosine-phosphorylated p130cas under these
conditions is most likely prohibited by the presence of pervana-
date bound to the active site cysteine residue of PTP-PEST
(Fig. 5 and reference 10), which effectively excludes the bind-
ing of phosphotyrosine residues of p130cas. The ability of the
C231S mutant PTP-PEST to associate in a stable complex with
p130cas in the presence of pervanadate again indicates that this
mutant protein is largely unaffected by pervanadate. As an
alternative to pervanadate treatment, COS cells cotransfected
with v-src and either wild-type or mutant PTP-PEST proteins
were used as a source of tyrosine-phosphorylated proteins.
Although the level of tyrosine phosphorylation observed in
these cells was much lower than that in pervanadate-treated
cells, a specific interaction between mutant PTP-PEST and
tyrosine-phosphorylated p130cas was again observed (data not
shown).
In summary, these observations lend further support to the
suggestion that the exclusive interaction between PTP-PEST
and tyrosine-phosphorylated p130cas, which we have consis-
tently observed, is entirely active site directed and therefore
reflects the genuine, inherent highly restricted substrate pref-
erence of PTP-PEST for p130cas.
DISCUSSION
The results described in this paper implicate p130cas as a
physiologically relevant substrate for PTP-PEST. Furthermore,
the observed stringency and exclusivity of the interaction be-
tween PTP-PEST and p130cas in a wide variety of cell lines
suggest that p130cas may be a unique high-affinity substrate for
PTP-PEST, although the possibility that other significant PTP-
PEST substrates exist cannot be excluded at present. In par-
ticular, it is unclear whether pervanadate-treated cells display
a complete spectrum of all possible tyrosine-phosphorylated
proteins; in fact, this appears unlikely, since pervanadate treat-
ment presumably results only in an increase in tyrosine phos-
phorylation of proteins which are to some extent constitutively
phosphorylated, but which are normally rapidly dephosphory-
lated, within the cell. Potential substrates lacking from per-
vanadate-treated cells therefore presumably include substrates
of protein tyrosine kinases which are normally present in an
inactive state, such as ligand-stimulated receptor protein ty-
rosine kinases and the recently described calcium-regulated
kinase PYK2 (28). Regardless of these considerations, the
ability of PTP-PEST to select p130cas exclusively as a substrate
from lysates of several different cell lines, containing a com-
bined total of at least 50 different potential substrates (many of
which presumably contain multiple sites of phosphorylation),
clearly demonstrates that the substrate specificity of PTP-
PEST is highly restricted.
Many intracellular PTPs are limited in their substrate avail-
ability because of strict confinement within a particular sub-
cellular location; examples include PTP1B, which is localized
to the cytoplasmic face of the endoplasmic reticulum (14), and
TCPTP, which is either nuclear (55) or localized to the endo-
plasmic reticulum, depending upon which alternative spliced
form is expressed (29). Alternatively, certain PTPs appear to
be highly regulated, requiring activation before appreciable
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activity can be demonstrated. For example, the SH2 domain-
containing PTPs, SHP1 and SHP2, display relatively little ac-
tivity in vitro, but can be considerably activated by several
mechanisms, including C-terminal truncation (65), addition of
certain phospholipids (66), or SH2 domain-mediated binding
of appropriate phosphotyrosine-containing peptides (26). How-
ever, PTP-PEST exhibits high specific activity in vitro (35,000
U/mg) and is a predominantly (90 to 95%) soluble PTP within
cells (16); in principle, therefore, it may act potently on any
substrate accessible to the cytoplasm. This accessibility may
partly underlie the necessity for PTP-PEST to possess an in-
herently constrained substrate specificity. The demonstration
that mutant PTP-PEST is capable of exclusively associating
with p130cas in an intracellular context (Fig. 6) in the presence
of many other tyrosine-phosphorylated proteins is an indica-
tion that the narrow substrate specificity of the enzyme may
result in PTP-PEST having a negligible influence on the phos-
phorylation state of the majority of tyrosine-phosphorylated
proteins within the cell, even though those substrates are large-
ly accessible to PTP-PEST.
The nature of the physiologically relevant tyrosine phos-
phorylation sites on p130cas is unknown. The larger splice vari-
ant of p130cas contains 31 tyrosine residues; 16 of these have
the sequence YxxP (45), which resembles the preferred bind-
ing site for the SH2 domain of the adapter protein Crk (52),
and it appears likely that a subset of these motifs within p130cas
represent in vivo phosphorylation sites (31, 43, 45, 46). p130cas
was initially identified as a prominent tyrosine-phosphorylated
protein in cells transformed by the viral oncogene v-crk (30, 32)
and by activated variants of src (23, 42). In both cases, tyrosine-
phosphorylated p130cas is associated with Src and Crk proteins
(24, 32, 42, 45), and these interactions appear to involve largely
SH2 domain-mediated binding of these proteins to phospho-
tyrosine residues within p130cas (24, 34). Optimal binding of
Src to p130cas also requires an intact Src SH3 domain (24),
which is thought to bind a proline-rich sequence (RPLPSPP) in
p130cas (34). The role of p130cas in cellular transformation by
the v-crk and v-src oncogenes is unclear, although there is a
general correlation between the level of tyrosine phosphoryla-
tion of p130cas and the degree of transformation in cells ex-
pressing different forms of Crk or Src (24, 31). Furthermore,
enhanced tyrosine phosphorylation of p130cas has also been
observed in cells transformed by c-Ha-ras and by ornithine de-
carboxylase overexpression (1); expression of antisense cDNA
encoding p130cas in these cells results in a partial reversion of
the transformed phenotype (1). These observations suggest
that aberrant tyrosine phosphorylation of p130cas is a common
feature of cells transformed by several disparate mechanisms
and that p130cas may be required for full manifestation of the
transformed state. Dephosphorylation of p130cas by PTP-
PEST is therefore a potentially important regulatory mecha-
nism for counteracting the transforming effects of various on-
cogenes.
Tyrosine phosphorylation of p130cas has been observed in
fibroblasts during integrin-mediated cell adhesion to extracel-
lular matrix proteins (35, 37, 57). Under these conditions, with
an antibody (4F4) that predominantly recognizes tyrosine-
phosphorylated p130cas (24, 37), it was shown that phosphor-
ylated p130cas is localized to focal adhesions (37), whereas
fractionation studies have demonstrated that the normal cel-
lular location of the majority of nonphosphorylated p130cas is
the cytosol (45). Furthermore, in crk-transformed fibroblasts,
tyrosine-phosphorylated p130cas is detected only in insoluble
fractions (45), suggesting that both cell adhesion-mediated
phosphorylation and transformation-mediated phosphoryla-
tion of p130cas are associated with redistribution of the protein
from the cytosol to focal adhesions. The precise mechanism of
this redistribution is unclear, but it was recently reported that
the SH3 domain of p130cas is capable of interacting with a
proline-rich region in the focal adhesion kinase, FAK (40). It is
therefore plausible that the redistribution of tyrosine-phosphor-
ylated p130cas may be driven by its association with FAK,
which is constitutively associated with focal adhesions due to
its C-terminal focal adhesion targeting domain (20, 47). The
sequestration of tyrosine-phosphorylated p130cas in focal ad-
hesions both in transformed cells and after integrin-mediated
cell adhesion strongly suggests a role for p130cas in signalling
events in this region of the cell. One consequence of the re-
distribution of tyrosine-phosphorylated p130cas is likely to be
that in addition to localizing p130cas to a region of the cell
containing abundant protein tyrosine kinase activity, the phos-
phorylated protein will be relatively inaccessible to the cytoso-
lic phosphatase PTP-PEST. This raises the possibility that the
role of PTP-PEST in dephosphorylating p130cas may be to
prevent inappropriate tyrosine phosphorylation of the cytosolic
pool of p130cas, thus preventing formation of signalling com-
plexes assembled around tyrosine-phosphorylated p130cas in
inappropriate cellular locations. In addition, a rapid dephos-
phorylation of p130cas has been observed during cell disaggre-
gation induced by disruption of the interaction between LFA-1
integrin receptors and ICAM-1 ligand molecules (38). This
observation supports a role for PTPs in regulating integrin-
mediated cell adhesion processes through the dephosphoryla-
tion of p130cas.
Previous studies have utilized active site cysteine mutant
variants of PTPs in order to investigate the substrate specificity
or substrate binding mechanism of these enzymes (18, 21, 33,
51, 53). Our data indicate that mutation of the invariant cata-
lytically essential aspartic acid residue (analogous to D199 in
PTP-PEST) generally results in PTPs with improved substrate-
trapping properties compared with active site cysteine mutants
(Fig. 3). There are two features of the D199A mutant that may
contribute to its ability to trap substrates more efficiently than
the cysteine mutant. First, during the catalytic process, a thiol-
phosphate intermediate is generated in which the active site
cysteine residue forms a covalent bond with the phosphate of
the substrate phosphotyrosine moiety (17). Normally at this
point in the reaction, hydrolysis of the bond between the phos-
phate moiety and the substrate tyrosine residue occurs, a re-
action which is catalyzed by the invariant aspartic acid residue.
In the absence of this aspartic acid residue, the lytic part of the
reaction occurs much more slowly; the substrate molecule is
therefore trapped by the direct interaction with the active site
cysteine. In addition, the substrate molecule is held by hydro-
phobic interactions arising from the movement of a loop in the
enzyme structure (residues 179 to 187 in PTP1B and 197 to 205
in PTP-PEST, within which the catalytically essential aspartic
acid residue normally resides) which partially closes the active
site cleft of the enzyme (21). The second feature of the aspartic
acid mutant protein which facilitates high-affinity interactions
with substrate molecules is the resultant loss of negative charge
on this loop of the protein. This modification is likely to result
in reduced electrostatic repulsion of the loop from the nega-
tively charged phosphate moiety of the substrate, allowing
more complete closure of the active site cleft and strengthen-
ing the hydrophobic interactions between the enzyme and the
tyrosine moiety of the substrate phosphotyrosine.
The identification of p130cas as a preferred substrate for
PTP-PEST supports the idea that some members of the PTP
family of enzymes may have specific physiological roles in de-
phosphorylation of particular tyrosine-phosphorylated substrates.
The methods outlined in this paper are generally applicable to
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any PTP and should therefore prove useful in delineating the
substrate preference of other PTP family members. In partic-
ular, the use of mutant, catalytically impaired PTPs to trap, and
thereby isolate, potential substrates will greatly facilitate the
identification of physiologically important substrates for indi-
vidual PTPs, leading to improved understanding of the roles of
these enzymes in regulation of cellular processes.
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